CSIMarket
 
Rapt Therapeutics Inc   (RAPT)
Other Ticker:  
 
 
Price: $8.4700 $0.06 0.713%
Day's High: $8.74 Week Perf: 4.57 %
Day's Low: $ 8.31 30 Day Perf: -66.85 %
Volume (M): 2,143 52 Wk High: $ 27.35
Volume (M$): $ 18,151 52 Wk Avg: $18.53
Open: $8.32 52 Wk Low: $6.86



 Market Capitalization (Millions $) 325
 Shares Outstanding (Millions) 38
 Employees 41
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -109
 Cash Flow (TTM) (Millions $) 15
 Capital Exp. (TTM) (Millions $) 1

Rapt Therapeutics Inc
Rapt Therapeutics Inc. is a publicly traded biopharmaceutical company that focuses on developing and commercializing small molecule therapies for cancer treatment. The company was founded in 2015 and is based in San Francisco, California.

Rapt Therapeutics aims to tackle cancer through a unique approach. The company leverages the concept of immunology to develop drugs that activate T cells in the body's immune system. T cells are a type of white blood cell that can recognize and attack cancerous cells. By targeting these cells, Rapt hopes to create a new class of cancer treatments that could be used alone or in combination with existing therapies like chemotherapy or radiation.

Rapt's platform technology is based on two molecules e FLX475 and RPT193 e which are designed to target two proteins that play key roles in regulating T cell activity. These two molecules work by inhibiting a negative feedback mechanism that can suppress the immune response, allowing T cells to become more active and responsive to cancer cells. Rapt believes that its approach has the potential to improve the efficacy and durability of cancer treatments by unleashing the full potential of our body's immune system.

The company has several clinical-stage programs underway that are investigating the potential of FLX475 and RPT193 in treating a variety of cancers. Early-stage clinical trials have demonstrated promising results, paving the way for more advanced studies. Rapt Therapeutics also plans to pursue further research into its platform technology to identify and develop additional drug candidates that target other T cell-regulating proteins.

Overall, Rapt Therapeutics is a company that is focused on advanced cancer treatment through immunology. By leveraging its platform technology, the company hopes to develop innovative new therapies that can improve patient outcomes and prolong survival rates for cancer patients worldwide.


   Company Address: 561 Eccles Avenue South San Francisco 94080 CA
   Company Phone Number: 489-9000   Stock Exchange / Ticker: NASDAQ RAPT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

RAPT Therapeutics Faces Investor Investigation for Potential Securities Law Violations

Published Tue, Mar 12 2024 1:00 AM UTC

As reported on March 11, 2024, prominent stockholder rights law firm Bragar Eagel & Squire, P.C. announced its investigation into RAPT Therapeutics, Inc. (NASDAQ: RAPT) on behalf of the company's stockholders. The law firm's probe aims to determine if RAPT has contravened federal securities laws or participated in any other unlawful business practices. This development adds ...

Clinical Study

Light at the End of the Itch: RAPT Therapeutics' Zelnecirnon Shows Promising Results in Groundbreaking Clinical Trial for Atopic Dermatitis

Published Mon, Nov 27 2023 1:01 PM UTC

RAPT Therapeutics Advances Treatment for Atopic Dermatitis with Promising Phase 1a/1b Clinical Trial of Zelnecirnon
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 - RAPT Therapeutics, a renowned clinical-stage biopharmaceutical company specializing in immunology-based therapies for inflammatory diseases and oncology, has made significant strides in the field with the publica...

Rapt Therapeutics Inc

Rapt Therapeutics Inc. Sets Path to Financial Transformation: Proactive Measures Underway


By
As the reporting season for July to September 2023 progresses, financial results of numerous entities, including several major pharmaceutical preparation companies, have been unveiled. Among these companies, Rapt Therapeutics Inc stands out, revealing an operating deficit of $-33.919 million for the fiscal period closing on September 30, 2023. Examining these recent financials, it is essential to assess the current state of the organization and the strategies being pursued to overcome this deficit.
Comparing the operating deficit of the third quarter of 2022, which stood at $-21.678 million, the recent figures indicate a significant expansion of financial challenges for Rapt Therapeutics Inc. The management is now actively seeking distinct business strategies in order to generate new revenue streams and alleviate the deficit.

Product Service News

RAPT Therapeutics' FLX475 and Checkpoint Inhibitor Combo Shows Promise in Phase 2 Trial, Boosting Treatment Prospects for Advanced NSCLC Patients

Published Fri, Nov 3 2023 4:00 PM UTC

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
RAPT Therapeutics, a clinical-stage immunology-based biopharmaceutical company, recently announced positive data from its Phase 2 clinical trial evaluating ...

Rapt Therapeutics Inc

Rapt Therapeutics Inc's 2023 Second Quarter Performance: Surprising Mix of Losses and Gains, Leaving Experts Intrigued



As the second quarter of the 2023 earnings season comes to a close, Rapt Therapeutics Inc, a clinical-stage biopharmaceutical company, has reported both positive and negative outcomes. While losses have expanded compared to the previous year, earnings per share have shown improvement. Meanwhile, the company's revenue remained unchanged.
During the second quarter of 2023, Rapt Therapeutics Inc experienced a loss of $-0.66 per share, compared to $-0.62 per share in the same reporting period a year ago. However, earnings per share improved from $-0.76 per share from the prior reporting period.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com